

**SEQUENT SCIENTIFIC LIMITED**  
**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2014**

(Rs in Lakhs)

S.No.	Particulars	CONSOLIDATED			
		Quarter Ended			Year Ended
		30-Jun-14 UNAUDITED	31-Mar-14 UNAUDITED	30-Jun-13 UNAUDITED	31-Mar-14 AUDITED
<b>Part-1</b>					
<b>1</b>	<b>Income from operations</b>				
a	Net Sales / Income from Operations (net of excise duty)	11,141.79	10,647.95	11,741.23	45,268.24
b	Other Operating Income	133.20	15.40	37.60	278.30
	<b>Total income from operations (net)</b>	<b>11,274.99</b>	<b>10,663.35</b>	<b>11,778.83</b>	<b>45,546.54</b>
<b>2</b>	<b>Expenses</b>				
a	Cost of materials consumed	4,672.10	6,491.90	5,006.50	23,972.20
b	Purchase of stock-in-trade	391.50	505.40	650.10	1,624.20
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,385.40	(1,042.50)	864.60	(1,223.90)
d	Employee benefits expenses	1,039.50	1,476.30	1,173.00	4,811.90
e	Depreciation and amortisation expenses	813.30	859.50	636.20	3,259.70
f	Other expenses	3,048.60	4,160.10	3,503.70	14,683.14
	<b>Total expenses</b>	<b>11,350.40</b>	<b>12,450.70</b>	<b>11,834.10</b>	<b>47,127.24</b>
<b>3</b>	<b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(75.41)</b>	<b>(1,787.35)</b>	<b>(55.27)</b>	<b>(1,580.70)</b>
<b>4</b>	<b>Other Income</b>	<b>198.70</b>	<b>305.40</b>	<b>78.60</b>	<b>384.20</b>
<b>5</b>	<b>Profit/(Loss) from ordinary activities before finance cost and exceptional items (3±4)</b>	<b>123.29</b>	<b>(1,481.95)</b>	<b>23.33</b>	<b>(1,196.50)</b>
<b>6</b>	<b>Finance cost</b>	<b>1,136.40</b>	<b>1,113.90</b>	<b>916.80</b>	<b>3,903.80</b>
<b>7</b>	<b>Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5±6)</b>	<b>(1,013.11)</b>	<b>(2,595.85)</b>	<b>(893.47)</b>	<b>(5,100.30)</b>
<b>8</b>	<b>Exceptional items</b>	<b>-</b>	<b>5,391.20</b>	<b>-</b>	<b>5,891.20</b>
<b>9</b>	<b>Profit/(Loss) from ordinary activities before tax (7±8)</b>	<b>(1,013.11)</b>	<b>(7,987.05)</b>	<b>(893.47)</b>	<b>(10,991.50)</b>
<b>10</b>	<b>Tax Expense</b>	<b>87.30</b>	<b>4.10</b>	<b>46.80</b>	<b>57.90</b>
<b>11</b>	<b>Net Profit/(Loss) from Ordinary activities after tax (9±10)</b>	<b>(1,100.41)</b>	<b>(7,991.15)</b>	<b>(940.27)</b>	<b>(11,049.40)</b>
<b>12</b>	<b>Extraordinary items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13</b>	<b>Net Profit/(Loss) for the period(11±12)</b>	<b>(1,100.41)</b>	<b>(7,991.15)</b>	<b>(940.27)</b>	<b>(11,049.40)</b>
<b>14</b>	<b>Share of profit/(Loss) of associates</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>15</b>	<b>Minority Interest</b>	<b>40.78</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>16</b>	<b>Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13±14±15)</b>	<b>(1,141.19)</b>	<b>(7,991.15)</b>	<b>(940.27)</b>	<b>(11,049.40)</b>
<b>17</b>	<b>Paid-up equity share capital (Face Value per share Rs.10 each)</b>	<b>2,733.52</b>	<b>2,733.52</b>	<b>2,419.52</b>	<b>2,733.52</b>
<b>18</b>	<b>Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year</b>				<b>133.50</b>
<b>19.i</b>	<b>Earnings Per Share before Extraordinary Items for the period (Non-Annualised)</b>				
	Basic (Rs.)	(4.17)	(29.46)	(3.91)	(42.76)
	Diluted (Rs.)	(4.17)	(29.46)	(3.91)	(42.76)
<b>19.ii</b>	<b>Earnings Per Share after Extraordinary Items for the period (Non-Annualised)</b>				
	Basic (Rs.)	(4.17)	(29.46)	(3.91)	(42.76)
	Diluted (Rs.)	(4.17)	(29.46)	(3.91)	(42.76)
<b>Part-II</b>					
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
<b>1</b>	<b>Public Shareholding</b>				
	No. of Shares	9,460,518	9,472,358	9,500,680	9,472,358
	% of Share Holding	34.61%	34.65%	39.27%	34.65%
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>				

	a) Pledged / Encumbered				
	1. No of shares	1,000,000	1,000,000	1,000,000	1,000,000
	2. Percentage of shares (as a % of the total shareholding of promoter & promoter group)	5.59%	5.60%	6.81%	5.60%
	3. Percentage of shares (as a % of the total share capital of the company)	3.66%	3.66%	4.13%	3.66%
	b) Non-encumbered				
	1. No of shares	16,874,673	16,862,833	13,694,511	16,862,833
	2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	94.41%	94.40%	93.19%	94.40%
	3. Percentage of shares (as a % of the total share capital of the company)	61.73%	61.69%	56.60%	61.69%
<b>B</b>	<b>INVESTOR COMPLAINTS</b>				
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	NIL			
	Disposed of during the quarter	NIL			
	Remaining unresolved at the end of the quarter	NIL			

**Notes:**

1. The unaudited consolidated financial results were taken on record by the Board of Directors at its meeting held on August 13, 2014.

## 2. Segment Results

The Company has identified Pharmaceuticals, Specialty Chemicals and Analytical Services as its business segments, Segments have been identified taking in to account the nature of products, the differing risks and returns, the organisational structure and the internal reporting system.

Sl. No	Particulars	Quarter Ended			Year Ended
		30-Jun-14 UNAUDITED	31-Mar-14 UNAUDITED	30-Jun-13 UNAUDITED	31-Mar-14 AUDITED
1	<b>Segment Revenue</b>				
	a) Pharmaceuticals	9,654.30	9,200.17	9,722.74	38,589.72
	b) Specialty Chemicals	1,365.90	1,196.23	1,791.96	6,022.28
	c) Analytical Services	254.79	266.95	264.13	934.54
	<b>Net Sales /Income from Operations</b>	<b>11,274.99</b>	<b>10,663.35</b>	<b>11,778.83</b>	<b>45,546.54</b>
2	<b>Segment Results</b>				
	<b>Profit or Loss before Tax and Interest from Each Segment</b>				
	a) Pharmaceuticals	(308.26)	(2,037.42)	(446.89)	(4,159.88)
	b) Specialty Chemicals	153.60	48.86	287.13	533.04
	c) Analytical Services	79.26	201.15	104.28	101.20
	<b>Total</b>	<b>(75.40)</b>	<b>(1,787.40)</b>	<b>(55.47)</b>	<b>(3,525.64)</b>
	Less (i) Finance Cost	1,136.40	1,113.90	916.80	3,903.80
	(ii) other unallocable expenditure net off unallocable income	(198.69)	5,085.75	(78.80)	3,562.06
	<b>Total Profit / (Loss) Before Tax</b>	<b>(1,013.11)</b>	<b>(7,987.05)</b>	<b>(893.47)</b>	<b>(10,991.50)</b>
3	<b>Capital Employed</b>				
	a) Pharmaceuticals	50,386.03	33,688.00	32,792.57	33,688.00
	b) Specialty Chemicals	3,363.00	2,942.10	1,795.60	2,942.10
	c) Analytical Services	457.57	423.30	565.10	423.30
	d) Unallocated	(29,373.90)	(30,922.80)	(26,082.27)	(30,922.80)
	<b>Total</b>	<b>24,832.70</b>	<b>6,130.60</b>	<b>9,071.00</b>	<b>6,130.60</b>

3. The Company has opted to publish consolidated financial results from the current financial year and accordingly the results for the quarter ended 31 March'14 and 30 June'13 are published for the first time

4. During the quarter the Company has issued 20 Lakhs warrants to its promoter group.

## 5. Discontinuing operations:

5a. During previous quarter, the Board of Directors of the Company had approved the transfer of Specialty Chemicals Division of the Company along with all related assets and liabilities by way of slump sale. The Specialty Chemicals Division is reported as part of the Specialty Chemicals segment of the Company. During the quarter requisite approval from the shareholders as per the provisions of Section 180(1)(a) of the Companies Act, 2013 has been obtained through postal ballot and in August 2014 it has completed the sale.

5b. The profit/(loss) of the discontinuing business included in the above is as follows:

Profit/(loss) of the discontinuing business included in the above	Quarter Ended			Year Ended
	30-Jun-14	31-Mar-14	30-Jun-13	31-Mar-14
Specialty Chemicals Division	(14.40)	(98.70)	143.50	(21.80)

## 6. Exceptional Items consists of:

6a. Sequent had developed certain non-infringing technologies/IPs in the complex area of Penems. However, the implementation of project got delayed due to delays in environmental approval from Government of India. Further, post the change of control of our key customer for the business, the Company was uncertain of their continued interest in the project. Given the significant additional investments involved to complete the project, the Company had decided to discontinue the project and write-down the related cost and investments of Rs.Nil (Rs.5,391.20 Lakhs for the quarter and Rs.5,391.20 Lakhs for the year ended 31 March 2014), which is included in exceptional items.

6b. Advance paid for purchase of shares amounting to Rs. 500 lakhs has been written off in the year ended 31 March 2014.

7. During the quarter, the Company has invested Rs.3,850 Lakhs in 35,00,000 equity shares of Shasun Pharmaceuticals Limited. Further, the Company has subscribed to 71,00,000 warrants of Shasun Pharmaceuticals Limited which is convertible into equivalent number of equity shares of face value of Rs.2 each. The Company has paid Rs.1,952.50 Lakhs as advance for subscription of these warrants.

## 8. Information on Standalone Results:

	Quarter Ended			Year Ended
	30-Jun-14	31-Mar-14	30-Jun-13	31-Mar-14

Total Income from operations (net)	10,972.70	10,366.30	11,361.20	44,508.40
Profit before Tax	(1,248.50)	(6,864.80)	(929.90)	(11,441.60)
Profit after Tax	(1,248.50)	(6,864.80)	(929.90)	(11,441.60)

9. The Group is in the process of assessing the potential impact of depreciation on adoption of Schedule II of the Companies Act 2013, which has come into effect from April 1, 2014. Pending such assessment, no adjustments have been made in these results.

10. Figures for previous periods have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

11. The standalone financial results of the Company are available in Company website [www.sequent.in](http://www.sequent.in) and website of Stock Exchange [www.bseindia.com](http://www.bseindia.com)

**For Sequent Scientific Limited**

Place : Bengaluru

Date : August 13, 2014

**Dr. Gautam Kumar Das**

**Joint Managing Director**